ArticleLeukemia2015

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.

M Cavo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.